United States Market for Rheumatoid Arthritis Pharmacotherapeutics

• Publication date: July 2012
• Report size: 110 pages

This research service covers the United States rheumatoid arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed used on top of background standard of care. Included in the study are products of the market and products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Treatment pa...

This research service covers the United States rheumatoid arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed used on top of background standard of care. Included in the study are products of the market and products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Treatment paradigms for rheumatoid arthritis and patient flow dynamics through lines of therapy are also included. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics, and novel oral disease-modifying antirheumatic drugs (DMARDs).

Executive Summary
•The market for rheumatoid arthritis (RA) pharmacotherapeutics that are prescribed as add-on therapy to background standards of care earned a revenue of approximately $x million in 2011.
•By 2017, total revenue for RA pharmacotherapeutics is expected to grow to $x million.
•The tumor necrosis factor (TNF) inhibitors Enbrel, Humira, and Remicade dominate the market as first-line standards of care and account for approximately x percent of the revenue in 2011.
•Amgen, Abbott, and Johnson & Johnson dominate the market almost equally, with Amgen maintaining a leading position by a small margin.
•The TNF inhibitors are well entrenched and are expected to continue to dominate the market by the end of the forecast period, albeit to a lesser degree.
•Novel oral antirheumatic drugs are anticipated to capture approximately xx percent of the market by 2017.
•New biologics arriving to the market will impact TNF market share as well. However, novel orals and biologics are generally reserved for anti-TNF refractory patients.
•The high cost of biologics make these essential therapies inaccessible to many patients, driving a need for less costly options without sacrificing safety or efficacy.
•Although overall disease prevalence is not expected to change significantly, the eligible patient population is expected to grow due to anticipated changes in clinical practice.

Pathology Industry in the United States

TABLE OF CONTENTS

Executive Summary 4
Market Overview 10
Total Rheumatoid Arthritis Pharmacotherapeutics Market -
External Challenges: Drivers and Restraints 25
Forecasts and Trends 41
Demand Analysis 53
Market Share and Competitive Analysis 55
TNF Inhibitor Segment Breakdown 69
Non-TNF Biologics Segment Breakdown 80
Novel Oral DMARDs Segment Breakdown 91
The Last Word (Conclusions and Implications) 99
Appendix 103

Musculoskeletal Disorder in United States

United States Osteoarthritis, 15-29 Yrs, Total, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States

United States Osteoarthritis, 30-44 Yrs, Total, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States

United States Osteoarthritis, 45-59 Yrs, Total, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States

United States Osteoarthritis, 70+ Yrs, Total, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States

United States Osteoarthritis, 60-69 Yrs, Total, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States

Pathology in United States

United States Respiratory Infections, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States

United States Protein-energy Malnutrition, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States

United States Respiratory Diseases, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States

United States Peptic Ulcer Disease, 0-4 Yrs, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States

United States Post-traumatic Stress Disorder, Total, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United States